Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primaquine efficacy is further complicated by both impacts of partner blood schizontocides and natural polymorphisms of cytochrome P450 2D6 impairing the necessary metabolic processing of primaquine [39–42].”
In the citing paper
“Primaquine efficacy is further complicated by both impacts of partner blood schizontocides and natural polymorphisms of cytochrome P450 2D6 impairing the necessary metabolic processing of primaquine [39–42].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria
Baird, J. K. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-12 · Cited by 398
Self-citationMcGready, R., Lee, S., Wiladphaingern, J., Ashley, E., Rijken, M., Boel, M., Simpson, J., Paw, M., Pimanpanarak, M., Mu, O., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70339-5 · Cited by 228
Research works printed but not linked: 31
- Howes, 2016, Global epidemiology of Plasmodium vivax., Am J Trop Med Hyg, 95, 15, 10.4269/ajtmh.16-0141 · DOI · Paper page
- Anstey, 2012, Plasmodium vivax: clinical spectrum, risk factors and pathogenesis., Adv Parasitol, 80, 151, 10.1016/B978-0-12-397900-1.00003-7 · DOI · Paper page
- Adekunle, 2015, Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo., PLoS Negl Trop Dis, 9, e0003595, 10.1371/journal.pntd.0003595 · DOI · Paper page
- Robinson, 2015, Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model., PLoS Med, 12, e1001891, 10.1371/journal.pmed.1001891 · DOI · Paper page
- Baird, 2016, Diagnosis and treatment of Plasmodium vivax malaria., Am J Trop Med Hyg, 95, 35, 10.4269/ajtmh.16-0171 · DOI
- Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map., PLoS Med, 9, e1001339, 10.1371/journal.pmed.1001339 · DOI · Paper page
- Price, 2014, Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis., Lancet Infect Dis, 14, 982, 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
- Marcsisin, 2016, Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art., Pharmacol Ther, 161, 1, 10.1016/j.pharmthera.2016.03.011 · DOI · Paper page
- Avula, 2013, Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13C stable isotope labeling., J Mass Spectrom, 48, 276, 10.1002/jms.3122 · doi:10.1002/jms.3122
- Pybus, 2013, The metabolism of primaquine to its active metabolite is dependent on CYP 2D6., Malar J, 12, 212, 10.1186/1475-2875-12-212 · DOI · Paper page
- Hicks, 2014, Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization., Curr Drug Metab, 15, 218, 10.2174/1389200215666140202215316 · doi:10.2174/1389200215666140202215316
- Zhou, 2009, Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I., Clin Pharmacokinet, 48, 689, 10.2165/11318030-000000000-00000 · DOI · Paper page
- Zanger, 2004, Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry., Naunyn Schmiedebergs Arch Pharmacol, 369, 23, 10.1007/s00210-003-0832-2 · DOI · Paper page
- Bennett, 2013, Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria., N Engl J Med, 369, 1381, 10.1056/NEJMc1301936 · DOI · Paper page
- Ingram, 2014, The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea., Malar J, 13, 488, 10.1186/1475-2875-13-488 · DOI
- Sutanto, 2013, Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia., Antimicrob Agents Chemother, 57, 1128, 10.1128/AAC.01879-12 · DOI
- Nelwan, 2015, Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia., BMC Med, 13, 294, 10.1186/s12916-015-0535-9 · DOI
- Gaedigk, 2008, The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype., Clin Pharmacol Ther, 83, 234, 10.1038/sj.clpt.6100406 · DOI · Paper page
- Wojtczak, 2007, CYP2D6 phenotyping with dextromethorphan., Pharmacol Rep, 59, 734
- Ito, 2010, Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature., Drug Metab Pharmacokinet, 25, 243, 10.2133/dmpk.25.243 · DOI · Paper page
- Abduljalil, 2010, Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan., Clin Pharmacol Ther, 88, 643, 10.1038/clpt.2010.137 · DOI
- Ward, 1984, Determination of primaquine in biological fluids by reversed-phase high performance liquid chromatography., J Chromatogr A, 305, 239, 10.1016/S0378-4347(00)83337-X · doi:10.1016/s0378-4347(00)83337-x
- Mould, 2013, Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods., CPT Pharmacometrics Syst Pharmacol, 2, e38, 10.1038/psp.2013.14 · DOI · Paper page
- Keizer, 2013, Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose., CPT Pharmacometrics Syst Pharmacol, 2, e50, 10.1038/psp.2013.24 · DOI · Paper page
- Lam, 1993, High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection., Ther Drug Monit, 15, 300, 10.1097/00007691-199308000-00007 · DOI
- Daali, 2008, Development and validation of a chemical hydrolysis method for dextromethorphan and dextrorphan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients., J Chromatogr B Analyt Technol Biomed Life Sci, 861, 56, 10.1016/j.jchromb.2007.11.019 · doi:10.1016/j.jchromb.2007.11.019
- Sistonen, 2007, CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure., Pharmacogenet Genomics, 17, 93, 10.1097/01.fpc.0000239974.69464.f2 · DOI · Paper page
- Baird, 2003, Primaquine for prevention of malaria in travelers., Clin Infect Dis, 37, 1659, 10.1086/379714 · DOI
- Baird, 2018, Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms., Malar J, 17, 42, 10.1186/s12936-018-2190-z · DOI
- Kitchen, 1949, Malariology: A Comprehensive Survey of All Aspects of This Group of Diseases From a Global Standpoint, 1037
- World Health Organization, 2015, Control and Elimination of Plasmodium vivax: A Technical Brief
Cited by
Battle, K. E., Lucas, T. C. D., Nguyen, M., Howes, R. E., Nandi, A. K., Twohig, K. A., Pfeffer, D. A., Cameron, E., Rao, P. C., Casey, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31096-7 · Cited by 409
Plasmodium vivax in the Era of the Shrinking P. falciparum Map
Price, R. N., Commons, R. J., Battle, K. E., Thriemer, K., & Mendis, K. (2020) · Trends in Parasitology · doi:10.1016/j.pt.2020.03.009 · Cited by 269
Satyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009610 · Cited by 12
Self-citation
Metadata
- Authors
- Baird, J. K., Louisa, M., Noviyanti, R., Ekawati, L., Elyazar, I., Subekti, D., Chand, K., Gayatri, A., Instiaty, Soebianto, S., Crenna-Darusallam, C., Djoko, D., Hasto, B. D., Meriyenes, D., Wesche, D., Nelwan, E. J., Sutanto, I., Sudoyo, H., & Setiabudy, R.
- Affiliations
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Department of Pharmacology, Faculty of Medicine Universitas Indonesia, Jalan Salemba Raya No. 6, Central Jakarta, Indonesia
- Eijkman Institute of Molecular Biology, Central Jakarta, Indonesia
- Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Central Jakarta, Indonesia
- Army Health Command, East Jakarta, Indonesia
- Certara Strategic Consulting, Princeton, New Jersey
- Division of Tropical Infectious Diseases, Faculty of Medicine, Universitas Indonesia, Central Jakarta, Indonesia
- Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Central Jakarta, Indonesia
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2018-08-31
- Volume
- 1
- Issue
- 4
- Pages
- e181449
- ISSN
- 2574-3805
- Cited by
- 94
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria. https://app.cochat.ai/papers/10.1001/jamanetworkopen.2018.1449
- The paper
- Baird, J. K., Louisa, M., Noviyanti, R., Ekawati, L., Elyazar, I., Subekti, D., Chand, K., Gayatri, A., Instiaty, Soebianto, S., Crenna-Darusallam, C., Djoko, D., Hasto, B. D., Meriyenes, D., Wesche, D., Nelwan, E. J., Sutanto, I., Sudoyo, H., & Setiabudy, R. (2018). Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2018.1449
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.